Coagulation factor II – fibrinogen interaction (FIIa-FI interaction)

The interaction between Coagulation factor II (Thrombin) and fibrinogen is the definitive step in the blood coagulation cascade, responsible for the transition from a fluid state to a solid clot. Thrombin, a highly specific serine protease generated from prothrombin, cleaves fibrinopeptides from the N-terminal regions of the fibrinogen alpha and beta chains, exposing polymerization sites that allow fibrin monomers to assemble into a stable mesh (StatPearls, 2023; UniProt P00734). This process is essential for physiological hemostasis but becomes a driver of pathology in conditions such as venous thromboembolism, atrial fibrillation-related stroke, and myocardial infarction (PubMed, PMID: 15730605). Therapeutic intervention typically focuses on inhibiting thrombin's enzymatic activity to prevent fibrinogen conversion. Direct thrombin inhibitors (DTIs) like dabigatran and bivalirudin bind directly to thrombin's active site or exosites, whereas indirect anticoagulants like heparin facilitate the inhibition of thrombin by antithrombin III (DrugBank, DB06695). Because this interaction is the final common pathway of coagulation, its modulation is highly effective for anticoagulation but carries a significant risk of bleeding complications (NIH, 2022). Monitoring of this interaction in clinical settings is often performed using the thrombin time (TT) or fibrinogen assays to ensure therapeutic efficacy and patient safety (StatPearls, 2023).

Other names

Thrombin-fibrinogen interactionFactor IIa-fibrinogen interactionFibrinogen cleavage by thrombinThrombin-catalyzed fibrin formation

Inhibition of the proteolytic activity of thrombin (Factor IIa) to prevent the cleavage of fibrinogen into fibrin monomers, thereby blocking the final step of the coagulation cascade and preventing stable clot formation.